Skip to main content
Premium Trial:

Request an Annual Quote

Patricia Beckmann, Robert Monaghan, Andre Lubarsky, Andrew Penman

Premium
The Oregon Translational Research and Drug Development Institute this week announced that Patricia Beckmann has been named its new executive director. Beckmann replaces Robert Monaghan, who was serving as director of OTRADI on an interim basis.
 
Beckmann was most recently a Kauffman Fellow at the Accelerator Corporation and a venture partner with the Northwest Technology Ventures fund. She has also served as the chief scientific officer for Homestead Clinical Corporation and as a biotechnology investment specialist for Vulcan Capital.
 

 
Cyntellect announced this week that Andre Lubarsky has been appointed as the director of sales for North America.
 
Prior to Cyntellect, Lubarsky was director of sales for North America at BD Biosciences Bioimaging Systems. Previously, he was national imaging sales manager at McBain Instruments and senior sales manager at Applied Imaging. Lubarsky's prior experience included other executive sales management positions with Leica, Bio-Rad Laboratories, and Cambridge Instruments
 

 
Southern Research Institute this week announced that Andrew Penman has been named vice president of its drug development division. Penman will lead SRI's preclinical contract research operations in toxicology, bioanalytical sciences, infectious diseases, cancer therapeutics, and immunology.
 

Before joining SRI, Penman served as vice president of preclinical development for Angiotech in Canada. Prior to that, Penman was president of preclinical technologies at Aptuit. He also held scientific management positions at Pharmacia in the US, Cephac Europe in France, and Quintiles in Scotland.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.